An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Cediranib (Primary) ; Ceralasertib (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Oleclumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Vistusertib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- Acronyms HUDSON
- Sponsors AstraZeneca; AstraZeneca AB
- 01 Mar 2024 Results evaluating combination regimens for advanced NSCLC following failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy, published in the Nature Medicine
- 10 Aug 2023 Planned End Date changed from 27 Feb 2025 to 26 Sep 2024.
- 10 Aug 2023 Planned primary completion date changed from 27 Feb 2025 to 26 Sep 2024.